Have you ever heard of the chronic disease, MASH? It is a progressive, chronic, metabolic liver disease that impacts more than 250 million people globally. It is often described as a ‘silent disease’ due to lack of symptoms and lack of awareness – all contributing to a delay in diagnosis. Thousands of liver specialists are at the #EASLCongress2024 in Milan to highlight new developments in MASH. We are looking forward to engaging peers from around the world, as we advance the science to help people living with this progressive disease. To learn more about MASH, click here: https://lnkd.in/dzRkrH8N #EASLCongress2024 #drivingchange #ActOnMASH
Chronic disease is also called Non- Communication disease ( NCD). Is part of the key surveillance disease of public health.
Addresses a very important unmet medical need.
Great to see the whole team on-site! 🙌
Hope Novo can lead the way to help cure this disease! Saunders is ready to help with the process to get you there!
Wonderful! Such an important disease to tackle.
Vice President | Clinical Development
1moJust came back from EASL 2024 in Milan. plenty of GLP-1 data across number of companies. It will be interested to see what GIP/Glucagon agonism to GLP-1 receptor affinity is ideal. What is the data on hyperglycemia (glucagon effect) and the d/c rate (perhaps a function of speed of dose escalation). Last but not least, the extent of anti-fibrotic effect (vs well known NASH resolution effects). I feel jury is still out on whether GIPR agonism or antagonist is way to go in diabetic NASH pts. So lot of exciting data to look forward to in this crowded field. Khurram